FDAnews
www.fdanews.com/articles/120656-neuralstem-receives-fda-approval-to-commence-first-als-stem-cell-trial

Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial

September 21, 2009
Neuralstem, Inc. announced that the FDA has approved its investigational new drug application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) with its spinal cord stem cells.
Yahoo! Finance